Mizuho Securities analyst Salim Syed has maintained their bullish stance on KURA stock, giving a Buy rating yesterday.
Salim Syed has given his Buy rating due to a combination of factors including the promising developments in Kura Oncology’s pipeline. The company is making significant progress with its KOMET-017 trial, having aligned with both the FDA and EMA on the trial protocol, and anticipates top-line results in 2028. This trial, which explores the use of ziftomenib in combination with chemotherapy for AML, is seen as a potential transformative opportunity in the market, which could reach over $7 billion annually in the U.S.
Additionally, the KOMET-001 trial has shown encouraging data, which has been submitted for presentation at ASCO and is aligned with the FDA submission package. The company is also preparing for a New Drug Application submission in 2025. Furthermore, Kura Oncology’s strategic focus on clinical collaborations and potential blockbuster opportunities in AML, GIST, and FTI indications supports the Buy rating, as these efforts are well-funded and poised to deliver substantial value.
KURA’s price has also changed dramatically for the past six months – from $20.540 to $7.770, which is a -62.17% drop .